Format

Send to

Choose Destination
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):441-51. doi: 10.1586/erp.10.49.

Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.

Author information

1
University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.

Abstract

Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no international consensus on the definition of multidrug resistance exists, making direct comparison of the literature difficult. Inappropriate empirical therapy has been associated with increased mortality in P. aeruginosa infections; delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with MDR infections owing to limited effective antimicrobial options. This article aims to summarize the contemporary literature on patient outcomes following infections caused by drug-resistant P. aeruginosa. The impact of antimicrobial therapy on patient outcomes, mortality and morbidity; and the economic impact of MDR P. aeruginosa infections will be examined.

PMID:
20715920
PMCID:
PMC3071543
DOI:
10.1586/erp.10.49
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center